S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Jaguar Animal Health Files for IPO

Photo of Chris Lange
By Chris Lange Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

puppies
Thinkstock
Jaguar Animal Health Inc. filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but it is valued up to $70 million. The company will list its common stock on the Nasdaq Capital Market under the symbol JAGX when it begins trading.

The underwriters for the offering are BMO Capital Markets, Roth Capital Partners and Guggenheim Securities.

Jaguar is an animal health company with its focus being in gastrointestinal products for companion and production animals. Canalevia is its lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. Neonorm is the lead non-prescription product to address the symptoms of watery diarrhea in pre-weaned dairy calves.

Jaguar has seven investigational new animal drug applications on file with the U.S. Food and Drug Administration (FDA) and it intends to develop species-specific formulations of Neonorm in six additional target species.

READ ALSO: Calithera Files for IPO to Fund Cancer Tumor Therapy Projects

Neonorm has a planned launch in the United States by the end of 2014. The additional formulations of Neonorm for other animal species are expected to launch in the beginning of 2015.

Jaguar’s goal is to become a leading animal health company that services both companion and production animal markets. The company plans to achieve this by leveraging its gastrointestinal knowledge, experience and intellectual property to develop a line of products across multiple market channels.

The net proceeds from this offering are planned to be allocated as such (all values are approximate):

  • $4.5 million for clinical studies related to Canalevia
  • $3.5 million for clinical studies related to prescription drug products for companion animals
  • $3.0 million for studies and registration activities outside the United States related to Neonorm
  • $2.0 million for the costs of developing other species-specific formulations
  • $10.0 million for establishing manufacturing capability
Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Jaguar Animal Health Gears Up for Secondary Offering
Chris Lange |

Jaguar Animal Health Gears Up for Secondary Offering

Jaguar Animal Health has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
Jaguar Animal Health Gears Up for Secondary Offering
Chris Lange |

Jaguar Animal Health Gears Up for Secondary Offering

Jaguar Animal Health has filed with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering of more than…
Jaguar Animal Health Stumbles on Secondary Offering
Chris Lange |

Jaguar Animal Health Stumbles on Secondary Offering

Jaguar Animal Health Inc. (NASDAQ: JAGX) filed a Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding a secondary…
Jaguar Animal Health Skyrockets on Stock Purchase Agreement
Chris Lange |

Jaguar Animal Health Skyrockets on Stock Purchase Agreement

Jaguar Animal Health shares absolutely skyrocketed in Thursday’s session following the announcement of a common stock purchase agreement.
PLx Pharma Gets Closer to IPO Debut
Chris Lange |

PLx Pharma Gets Closer to IPO Debut

More than 3 million PLx Pharma shares are expected to price in the range of $17 to $19 per share…
Blazing Biotechs Highlight Stocks Trading Under $10 With Massive Upside Potential
Lee Jackson |

Blazing Biotechs Highlight Stocks Trading Under $10 With Massive Upside Potential

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential.…
BioXel Gears Up for IPO
Chris Lange |

BioXel Gears Up for IPO

Clinical-stage biopharmaceutical company BioXel Therapeutics has filed with the SEC regarding its initial public offering.
Celator Pharma Prices Secondary Offering
Chris Lange |

Celator Pharma Prices Secondary Offering

Celator Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
Chris Lange |

Protagonist Therapeutics Files for IPO

Protagonist Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618